 |
Prof. W. Graham Richards
Non-Executive Director and Founder
|
|
Professor W. Graham Richards is one of the leading computational chemists in the UK, with over 300 publications. He served as Chairman of the Department of Chemistry at Oxford University from 1997 to 2007. He is head of the Centre for Computational Drug Discovery at Oxford. Throughout his career, Professor Richards has been involved in the commercialization of technologies. In 1989, he co-founded Oxford Molecular Ltd, which later floated on the London Stock Exchange as Oxford Molecular Group plc. In 2001, he founded InhibOx Ltd. He was a director of ISIS Innovation Ltd, the University of Oxford's technology transfer company and was involved for several years with the Wellcome Trust in a similar capacity. He is a main board director (formerly Chairman) of IP Group plc, the listed intellectual property commercialization company. |
|
|
|
 |
Dr Paul Finn
Chief Scientific Officer
|
|
Paul completed his undergraduate degree at St Peter's College, Oxford and his biochemistry Ph.D. at the University of Manchester. Between 1985 and 1990, he worked as a scientist in the computational chemistry group at SmithKline Beecham, where he focused on the discovery of novel antibiotic agents. In 1990, he moved to Pfizer's computational chemistry group where he was responsible for developing Pfizer's in-house approach to virtual screening. In 1998, Paul joined Prolifix, a UK biotechnology company which was acquired in 2002 by TopoTarget, a listed drug development company focused on oncology. Following this acquisition Paul became group director of R&D and was responsible for TopoTarget's extremely successful HDAC inhibitor programme (now in Phase III trials).
 |
|
|
|
 |
Paul Davie
Chief Executive Officer
|
|
Paul has a long and successful track record in commercial roles in computer-aided drug discovery. He held support and sales roles at Chemical Design before going on to build and manage the European sales, marketing, support and consulting operations at Oxford Molecular. Paul went on Accelrys to build the Consulting Division and serve as European General Manager, before becoming Chief Operating Officer at InforSense. He founded and was CEO at Secerno, a successful database security company, before returning to research informatics with his consulting company, Davinger. Paul has an MBA and studied chemistry at Oxford University.
|
|
|
|
 |
Dr Garrett M. Morris
Research Manager
|
|
Dr Garrett M. Morris completed a D.Phil. in computational chemistry at the Physical and Theoretical Chemistry Laboratory, Oxford. He developed one of the first sequence analysis programs in bioinformatics, which was later distributed by Oxford Molecular, Ltd as Cameleon. In 1991, Dr. Morris joined the laboratory of Prof. Arthur J. Olson in the Department of Molecular Biology at The Scripps Research Institute in La Jolla, California, USA, where he contributed to AutoDock, the first flexible ligand-protein docking software. He helped to introduce novel and efficient search methods into AutoDock, developed a novel scoring function to estimate the free energy of binding of a ligand-protein complex, and introduced sidechain flexibility into the protein. In 2001 he helped to launch the first biomedical internet grid computing project, FightAIDS@Home using AutoDock, with Entropia. Dr Morris also collaborated in a multi-disciplinary structure-based drug design project, working extensively on HIV Protease, funded by the AIDS Structural Biology Program of the NIH, USA. Dr. Morris joined InhibOx in August 2008.
|
